MedTrace Logo

Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

NCT07311330 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-30

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction

Conditions

Interventions

DRUG

YN001 20mg Dose + 5% glucose injection

The treamtment group was given YN001 20 mg, once a week (QW), cumulative administration for 12 weeks (about 3 months)

OTHER

5% glucose injection

The control group was given placebo once a week (QW), cumulative administration for 12 weeks (about 3 months)

Sponsors & Collaborators

  • Beijing Inno Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-06-16
Completion
2026-11-14

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07311330 on ClinicalTrials.gov